GLPwatch

Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor.

Mol Cell Endocrinol · 2010

Last updated 2026-05-28

In lab tests, a GLP-1 drug called exendin-4 increased the growth of human coronary artery cells in a dose-dependent way, meaning higher doses led to more cell growth. This effect was blocked when certain pathways (PKA, PI3K, Akt, or eNOS) or the GLP-1 receptor were inhibited, showing these are required for the response.

AI summary of the abstract below.

JournalMol Cell Endocrinol, 2010
Citations201
Relative citation ratio5.51
NIH percentile93
Molecules
Conditions studied Cardiovascular Risk Reduction

Abstract

Endothelial cells have a robust capacity to proliferate and participate in angiogenesis, which underlies the maintenance of intimal layer integrity. We previously showed the presence of the GLP-1 receptor in human coronary artery endothelial cells (HCAECs) and the ameliorative actions of GLP-1 on endothelial dysfunction in type 2 diabetic patients. Here, we have studied the effect of exendin-4 on cell proliferation and its underlying mechanisms in HCAECs. Incubation of HCAECs with exendin-4 resulted in a dose-dependent increase in DNA synthesis and an increased cell number, associated with an enhanced eNOS and Akt activation, which were inhibited by PKA, PI3K, Akt or eNOS inhibitors and abolished by a GLP-1 receptor antagonist. Similar effects were obtained by applying GLP-1 (7-36) or GLP-1 (9-36). Co-incubation of exendin-4 and GLP-1 did not show additive effects. Our results suggest that exendin-4 stimulates proliferation of HCAECs through PKA-PI3K/Akt-eNOS activation pathways via a GLP-1 receptor-dependent mechanism.

Verbatim abstract via PubMed 20452396 ↗